Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia

Blood

Volumn 93, Issue 12, 1999, Pages 4086-4095

  Hu, Xiu F ^b   Slater, Alison ^b   Kantharidis, Phillip ^b   Rischin, Danny ^b   Juneja, Surender ^b   Rossi, Ralph ^b   Lee, Grace ^b   Parkin, John D ^b   Zalcberg, John R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; CYTARABINE; DAUNORUBICIN; EPIRUBICIN; GLYCOPROTEIN P; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CYTOPATHOGENIC EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033564958     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4086     Document Type: Article

References (62)

1. McKenna SL, Padua RA: Review: Multidrug resistance in Leukemia. Br J Haematol 96:659, 1997
2. Rothenberg M, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack D, Fojo AT: Expression of the mdr 1/P-170 gene in patients with acute lyraphoblastic leukemia. Blood 74:1388, 1989
3. Higgins CE: ABC transporters from microorganism to man. Annu Rev Cell Biol 8:67, 1992
4. Goldstein LJ, Pastan P, Gottesman MM: Review article: Multidrug resistance in human cancer. Crit Rev Oncol Haematol 12:243, 1992
5. Nüssler V, Fleischer RP, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H: P-glycoprotein expression in patients with acute leukemia - Clinical relevance. Leukemia 10:S23, 1996 (suppl 3)
6. Poeta GD, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papat G: Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87:1997, 1996
7. Beck J, Handgretinger R, Kinggebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V: Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 10:426, 1996
8. Zhou DC, Zittoun R, Marie J-P: Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9:1661, 1995
9. List AF, Spier CS, Grogan TM, Jonson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of major vault transport protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464, 1996
10. Legrand O, Simornin G, Rerrot JY, Zittoun R, Marie JP: Pgp and MRP activities using calcein-AM are prognostic factors in acute myeoloid leukemia patients. Blood 91:4480, 1998
11. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM: Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265:221, 1990
12. Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Fos F, Rosen N, Fojo AT: Modulation of the expression of multidrug resistance gene (MDR1/P-glycoprotein) by differentiating agents. J Biol Chem 264:18031, 1989
13. Gekeler V, Beck J, Noller A, Wilisch A, Fresc G, Neumann M, Handgretinger R, Ehninger G, Probst H, Neithammer: Drug-induced changes in the expression of MDR-associated gene: Investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 69:S19, 1994
14. Manzano RG, Wright VK, Twentyman PR: Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer 32A:2136, 1996
15. Hu X.F, Slater S, Wall DM, Kantharidis P, Parkin JD, Cowman A, Zalcberg JR: Rapid upregulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71:931, 1995
16. Hu, XF, Slater S, Rischin D, Kantharidis P, Parkin JD, Zalcberg JR: Induction of MDR1 gene expression by anthracyclines analogues in a human drug resistant leukemia cell line. Br J Cancer 79:831, 1999
17. Kohno K, Sato S, Takano H, Matsuo K-I, Kuwano M: The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 165:1415, 1989
18. Chin KV, Chauhan SS, Pastan I, Gottesman MM: Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1:361, 1990
19. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246:186, 1997
20. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632, 1993
21. Hu XF, Slater A, Wall DM, Parkin JD, Kanthrarids P, Zalcberg JR: Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 2:713, 1996
22. Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD, Vrazas V, Campbell L, Kantharidis P: Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57:522, 1994
23. Barber L, Rossi R, Prince HM, Bertoncello I: Fluoro-Gold as an alternative viability stain for multi-colour flow cytometric analysis. Cytometry (in press)
24. Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, Colosetti P, Cazin JL, De Cremoux P, Delvincourt C, Demur C, Drenou B, Fenneteau O, Feuillar J, Garnier-Suillerot A, Genne P, Gorisse M-C, Gosselin P, Jouault H, Lacave R, Le Calvez G, Léglise M-C, Léonce S, Manfait M, Maynadié M, Merle-Béral H, Merlin JL, Mousseau M, Morjani H, Picard F, Pinguet F, Poncelet P, Racadot E, Raphael M, Richard B, Rossi J-F, Schlegel N, Vielh P, Zhou DC, Robert J: French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris: Multicentric evaluation of MDR phenotype in Leukemia. Leukemia 11:1086, 1997
25. Marie JP, Legrand O, Perrot JY, Chevillard S, Huet S, Robert J: Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations. Semin Hematol 34:63, 1997 (suppl 5)
26. Broxterman HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ: Quality control of multidrug resistance assay in adult acute leukemia: Correlation between assay for P-glycoprotein expression and activity. Blood 87:4809, 1996
27. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ: Functional detection of MDR/P170 and MRP/P190 mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72:543, 1995
28. Keshelava N, Seeger R, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58:5396, 1998
29. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS: P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood 81:490, 1993
30. Kantharidis P, El-Osta S, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR: Altered methylation of the human MDR1 promoter is associated with acquied multidrug resistAnce. Clin Cancer Res 3:2025, 1997
31. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, Kozuru M, Kozuru M, Komatsu H, Ueda R, Kuwano M: Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92:4296, 1998
32. Rohlff C, Glazer RI: Regulation of multidrug resistance through the c-AMP and EGF signalling pathways. Cell Signal 7:431, 1995
33. Tanimura H, Kohno K, Sato SI, Uchiumi T, Miyazaki M, Kobayashi M, Kuwano M: The human multidrug resistance 1 promoter has an element that responses to serum starvation. Biochem Biophys Res Commun 183:917, 1992
34. Ferrandis E, Benard J: Activation of the human MDR1 gene promoter in differentiated neuroblasts. Int J Cancer 54:987, 1993
35. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267, 1992
36. Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi, T, Saijo N: 3′-Deamino-3′-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res 50:4698, 1990
37. Osborn MT, Chambers TC: Role of the stress-activated/c-jun NH2-terminal protein kinase pathway in cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271:30950, 1996
38. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, Kohno K: Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273:5997, 1998
39. Ip YT, Davis RJ: Signal transduction by the c-jun N-terminal kinase (JNK)- from inflammation to development. Curr Opin Cell Biol 10:205, 1998
40. Kolesnick R, Fuks Z: Ceramide: A signal for apoptosis or mitogenesis? J Exp Med 181:1949, 1995
41. Huwiler A, Brunner J, Hummel R, Vervoordeldonk M, Stable S, van de Bosch H, Pfeilschifter J: Ceramide-binding and activation defines protein kinase c-raf as a ceramide-activated protein kinase. Proc Natl Acad Sci USA 93:6959, 1996
42. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Friedman AH, Fuks Z, Kolesnick RN: Requirement for ceramide initiated SAPK/JNK signalling in stress induced apoptosis. Nature 380:75, 1996
43. Herr I, Wihelm D, Böhler T, Angel P, Debatin KM: Activation of CD95 (APO-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16:6200, 1997
44. Cornwell MM, Smith DE: A signal transduction pathway for activation of the mdrl promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268:15347, 1993
45. Kim SH, Lee SH, Kwak NH, Kang CD, Chung BS: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98:199, 1996
46. Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, Bates SE: Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin Cancer Res 1:1581, 1995
47. Gekeler V, Boer R, Überall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schächtele C, Klemm K, Grunicke H: Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 74:897, 1996
48. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, Gottesman MM: Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271:1708, 1996
49. Caponigro F, French RC, Kaye SB: Protein kinase C: A worthwhile target for anticancer drugs? Anticancer Drugs 8:26, 1997
50. Fine RL, Chambers TC, Sachs CW: P-glycoprotein, multidrug resistance and protein kinase C. Stem Cells 14:47, 1996
51. Porta CL, Dolfini E, Comolli R: Inhibition of protein kinase C-α enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. Br J Cancer 78:1283, 1998
52. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V: Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 10:426, 1996
53. Beck J, Regele B, Brügger D, Dietl J, Scheper RJ, Niethammer D, Bader P, Hirsch HA, Gekeler V: Expression of genes (MDR1, MRP, LRP, topoisomerases, PKC isozymes) possibly involved in drug resistance of ovarian carcinoma ascites cell aspirates. Proc Am Assoc Cancer Res 37:309, 1996
54. Beck J, Bohnet B, Brügger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethanmmer D, Gekeler V: Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKOη with MDR1, MRP and LRP gene expression. Br J Cancer 77:87, 1998
55. Uchiumi T, Kohno K, Tanimura H, Hidaka K, Asakuno K, Abe H, Uchida Y, Kuwano M: Involvement of protein kinase in environmental stress-induced activation of human multidrug resistance 1 (MDR1) gene promoter. FEBS Lett 326:11, 1993
56. Blobe GC, Stribling S, Obeid LM, Hannun YA: Protein kinase C isoenzymes: Regulation and function. Cancer Surv 27:213, 1996
57. Kharbanda S, Datta R, Kufe D: Regulation of c-Jun gene expression in HL60 leukemia cells by 1-β-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. Biochemistry 30:7947, 1991
58. Brach MA, Herrmann F, Kufe DW: Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood 79:728, 1992
59. Saleem A, Datta R, Yuan ZM, Kharbanda S, Kufe D: Involvement of stress activated protein kinase in the cellular response to 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ 6:1651, 1995
60. Kharbanda S, Emoto Y, Kisaki H, Saleem A, Kufe D: 1-β-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol 46:67, 1994
61. Piperno AG, Nolan P, Inaba K, Sterinman RM: The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. J Exp Med 172:1869, 1990
62. Clardy J: The chemistry of signal transduction. Proc Natl Acad Sci USA 92:56, 1995